Scinai Immunotherapeutics Ltd.
SCNI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $658 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $1,238 | $513 | $560 | $748 |
| Gross Profit | -$580 | -$513 | -$560 | -$748 |
| % Margin | -88.1% | – | – | – |
| R&D Expenses | $5,532 | $5,210 | $5,765 | $3,249 |
| G&A Expenses | $0 | $0 | $0 | $7,717 |
| SG&A Expenses | $2,526 | $4,505 | $5,296 | $7,625 |
| Sales & Mktg Exp. | $0 | $0 | $0 | -$92 |
| Other Operating Expenses | $0 | -$9 | $0 | -$12 |
| Operating Expenses | $8,058 | $9,706 | $11,061 | $10,862 |
| Operating Income | -$8,638 | -$9,706 | -$11,061 | -$10,874 |
| % Margin | -1,312.8% | – | – | – |
| Other Income/Exp. Net | $13,434 | $3,215 | $5,265 | $2,668 |
| Pre-Tax Income | $4,796 | -$6,500 | -$5,796 | -$8,206 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $4,796 | -$6,500 | -$5,796 | -$8,206 |
| % Margin | 728.9% | – | – | – |
| EPS | 6 | -16.8 | -30.8 | -87.6 |
| % Growth | 135.7% | 45.5% | 64.8% | – |
| EPS Diluted | 6 | -16.8 | -30.8 | -80 |
| Weighted Avg Shares Out | 806 | 391 | 189 | 103 |
| Weighted Avg Shares Out Dil | 806 | 391 | 189 | 141 |
| Supplemental Information | – | – | – | – |
| Interest Income | $100 | $123 | $8,098 | $1 |
| Interest Expense | $1,439 | $8 | $5,047 | $3,364 |
| Depreciation & Amortization | $1,649 | $514 | $562 | $471 |
| EBITDA | -$6,989 | -$9,192 | -$10,499 | -$10,391 |
| % Margin | -1,062.2% | – | – | – |